Skip to main content

Recently, the therapeutic potential of magic mushrooms in managing mental health disorders, particularly depression, has gathered significant interest. An emerging trend involves taking a standard dose of approximately 25 mg of the active component available at a mushroom dispensary. This dosage shows promise in providing relief and could complement conventional depression treatments.

A scholarly team’s research suggests that psilocybin, the active ingredient in magic mushrooms, has demonstrated promising results in treating depression.

Key Insights:

  • Psilocybin could alleviate depression symptoms in as little as eight days.
  • Side effects of psilocybin are generally mild to moderate and well-tolerated.
  • A 25mg dose of psilocybin can induce perception changes, mood shifts, enhanced creativity, and a sense of unity.

A Single Dose Can Suffice

A recent study used a rigorous methodology, employing a randomized, multi-blinded structure to contrast a single dose of psilocybin with an active placebo (niacin). The study evaluated the onset, duration of benefits, and safety profile of psilocybin over six weeks.

The Study Participants

The research targeted individuals aged 21 to 65 who met the Major Depressive Disorder (MDD) criteria as specified in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) and were undergoing a depressive episode lasting at least 60 days at the time of the study.

The Procedure

Participants received either a single 25-mg oral dose of psilocybin or a 100-mg dose of niacin, which acted as an active placebo, creating an immediate physiological response (flushing) designed to maintain the blinding integrity.

The psilocybin and niacin placebo were both administered following a standard “set and setting” protocol. There were two facilitators for the preparatory sessions, which lasted between 6 and and delve into a profound understanding of your existence.

The dosing period lasted between 7 and 10 hours, carried out in a relaxed environment. Four hours after the dosage, participants were motivated to introspect and share their experiences.

Insights from the Study

Just eight days after administering psilocybin, there was a noticeable decrease in depression symptoms. This promising effect remained consistent throughout the six-week follow-up period. The Montgomery-Asberg Depression Rating Scale (MADRS) showed increased response and remission rates when compared to other psilocybin studies and Treatment-Resistant Depression.

Psilocybin showed superior results in psychosocial functioning when compared to niacin. It demonstrated potential in several areas, including reducing the severity of the disease, anxiety, self-reported depressive symptoms, and improving the quality of life.

Most participants tolerated the compound well, with only minor or moderate side effects, mainly observed during the first dose. However, psilocybin treatment showed more frequent and severe side effects than niacin, which is consistent with our current understanding of its effects.

The researchers noted that psychedelics like psilocybin could cause side effects that standard rating scales might not always identify. They could also reveal previously undetected psychiatric conditions, even while effectively managing specific syndromes.

What Does a 25-mg Dose Entail?

A standard psychedelic dose is typically 15 to 25 milligrams of psilocybin (1.5 to 2.5 grams of dried mushrooms). This is the usual dosage for those seeking the full psychedelic effects of magic mushrooms.

This dosage can lead to changes in perception, mood alterations, increased creativity, and a feeling of unity with one’s surroundings. While slight visual effects might be encountered, intense hallucinations are not typical. It’s akin to entering a vivid dream-like world where reality merges effortlessly with an intriguing fusion of visual and auditory sensations.

The euphoric feelings often manifest as dance, subtle movements, or simply succumbing to the psychedelic rhythm. The experience typically lasts between 4 to 8 hours. At this level, visual distortions may become more pronounced. Patterns appear to move and morph, and your surroundings seem to pulsate with energy.

This dosage can be controlled but necessitates a secure setting and a positive mindset. It offers a journey filled with wonder and awe, inspiring you to delve into the depths of consciousness and gain a deeper understanding of your existence.

with careful excitement.

  • Improved color perception that is more notable.
  • Vision alterations, such as objects seeming to move or “breathe”.
  • Sensing synesthesia, such as “seeing sounds” or “hearing colours”.
  • Obtaining a deeper appreciation of music.
  • Frequent fits of laughter.
  • Altered touch sensations.
  • Engagement in introspection.
  • Feeling euphoric.
  • Differences in time perception.
  • Increase in heart rate and blood pressure.

Products Found in Magic Mushroom Stores

Magic mushroom stores carry an array of psilocybin-included products. These stores offer a variety of choices such as dried mushrooms, edibles, capsules, drinks, and more. Dried mushrooms are particularly sought after. 

Health Canada recognizes over 200 species of magic mushrooms, with Psilocybe cubensis being a commonly sold type. This strain is available in several variants, providing a vast selection for customers, similar to the offerings at cannabis dispensaries.

More Shroom Products:

EdiblesFood products like gummies and chocolates that are infused with psilocybin.
The dosage is made easy as the manufacturers provide the quantity per serving.
CapsulesThese are flavorless and can be easily integrated into your health routine. 
They contain minimal amounts to ensure a mild enhancement to your regimen.
BeveragesSimilar to edibles, but in a drinkable form.
They are flexible and come in options like chocolate, coffee, or tea.

Deciding Your Dose at Magic Mushroom Dispensaries

Even though magic mushrooms are not typically used to treat depression, Canada has taken a progressive step. They have permitted the examination and medicinal use of psilocybin, a Schedule I substance under the Controlled Drugs and Substances Act, for specific patients battling severe major depressive disorder. This decision could potentially benefit tens of thousands

Those dealing with anxiety and depression often seek out alternative forms of treatment through clinical trials.

Commonly Asked Questions

Can I buy psilocybin from a medicinal mushroom dispensary?

A medicinal mushroom dispensary usually offers products like Reishi, Turkey Tail, and Lion’s Mane. For those curious about the world of mushrooms, an online magic mushroom dispensary could be a suitable option. These dispensaries specialize in various mushroom products, including dried mushrooms and other psychedelic substances.

Is a 25 mg dosage appropriate for treating depression?

Research into suitable psilocybin dosages for depression treatment is still underway. Some studies focus on lower dosages, while others examine the effects of higher psilocybin amounts. A potential approach could involve starting with a microdose and gradually raising the dosage.

Can I buy shrooms in Toronto?

Online mushroom vendors allow shopping from anywhere in Canada. Regardless of your province or city, these online platforms ensure delivery to your doorstep.

What is the most affordable product in an online mushroom shop?

Dried mushrooms tend to be the most popular item among customers due to the variety of quantities available. The price can fluctuate based on whether you’re purchasing a small amount like 1 gram or bulk quantities. While edibles and other products are reasonably priced, they may not be as economical as dried mushrooms.

Can a single dose of shrooms help alleviate depression?

Some studies indicate that a single dose may be enough to lessen symptoms of depression. However, it’s important to remember that these studies usually involve participants also engaging in talk therapy alongside the treatment. This combination of psychedelic therapy and therapeutic discussion appears to yield the best results.

About the Author

The authors of this article include Charles L. Raison and colleagues; Jeremy D. Coplan, MD and Dorothy P. Reddy, MD; Albert Garcia-Romeu, Frederick S Barrett, Theresa M Carbonaro, Matthew W Johnson, and Roland R Griffiths; and Vince Polito.

Richard J. Stevenson, Rebecca Smausz, Joanna Neill, and John Gigg were also involved.

Affiliated Institutions:

  • Usona Institute in Fitchburg, Wisconsin
  • SUNY Downstate Medical Center in Brooklyn, New York
  • Neurogenesis Clinics in Brooklyn, New York
  • The Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine in Baltimore, MD, USA
  • Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine in Baltimore, MD, USA
  • Department of Neuroscience at Johns Hopkins University School of Medicine in Baltimore, MD, USA
  • Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, Baltimore, USA
  • Department of Cognitive Science at Macquarie University in Sydney, Australia
  • Department of Psychology at Macquarie University in Sydney, Australia
  • The Division of Neuroscience and Experimental Psychology, part of the Faculty of Biology, Medicine, and Health at The University of Manchester, Manchester, UK
  • Division of Pharmacy and Optometry, part of the Faculty of Biology, Medicine, and Health at The University of Manchester in Manchester, UK
  • Medical Psychedelics Working Group, in association with Drug Science, UK

Leave a Reply